While no SHCBP1-specific inhibitors have yet been implemented clinically, preclinical investigations utilizing genetic and pharmacological interventions have demonstrated that targeting SHCBP1 can suppress tumor growth and improve treatment outcomes. The gene discussed is SHCBP1; the disease is neoplasm.